IGHE and Eczematoid dermatitis: At baseline prior to initiation of dupilumab, 15 patients (75%) had IgE levels recorded, with an overall mean (± SD) of 1567.7 (± 3270.1) IU/mL (range 2 to 12,760 IU/mL); 8 (40%) had high IgE levels, defined as IgE ≥ 200 IU/mL [45] Mean (± SD) eczema area severity index (EASI) score at baseline was 41.9 (± 8.8) (range: 25–55).